|Bid||0.00 x 1100|
|Ask||0.00 x 1200|
|Day's Range||122.26 - 127.86|
|52 Week Range||68.11 - 128.82|
|Beta (3Y Monthly)||1.48|
|PE Ratio (TTM)||83.76|
|Earnings Date||May 22, 2019 - May 28, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||127.94|
National Vision (EYE) has been witnessing positive comps owing to increased customer transaction over the last 68 sequential quarters.
A study by TeleFlex (TFX) sheds light on the real-world retrospective data on 30 men suffering urinary retention treated with the UroLift System.
The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
Phibro Animal (PAHC) has been gaining from strong volume growth in foreign markets. However, adverse currency movements remain a concern.
Looking for the best growth stocks to buy? Start by identifying the seven traits of winning stocks, then use IBD screens to find stocks showing them now.
"The Cloud" has evolved from a budding innovation in tech to one of the largest factors driving growth in the technology sector in only a few years. So check out these three Zacks buy-ranked cloud stocks to consider right now.
Veeva Systems shows how to proactively protect your profits when investing in stocks, and why you should never risk letting a good gain disappear.
Veeva Systems (VEEV) today announced that life sciences companies are adopting Veeva Nitro to accelerate their data warehouse projects and deliver faster insights to the business. Veeva Nitro is a life sciences-specific commercial data warehouse that eliminates the time and effort of custom data warehouses and provides a foundation for artificial intelligence (AI) and advanced analytics. In half a year since the product’s availability, six companies have selected Veeva Nitro, including Karyopharm Therapeutics (KPTI) and MannKind Corporation (MNKD), with both customers live and using the product in under five months.
Zimmer Biomet (ZBH) has been working to strengthen foothold in emerging markets. However, the company has been facing continued pricing pressure.
The latest nod from Medicare Coverage for Myriad's (MYGN) myPath Melanoma test is likely to boost top-line results in the near term.
Align Technology (ALGN) will be integrating Digital Smile Design's methodology in functional and aesthetic dentistry with its end-to-end digital workflow covering iTero scanners and Invisalign system.
Receipt of the CE Mark followed by a limited launch of the WATCHMAN FLX device in Europe is likely to drive top-line contributions from Boston Scientific's (BSX) IC suite.
Hologic (HOLX) looks stronger than Varian Medical (VAR) when it comes to current-year earnings projections as well as fundamentals.
QIAGEN (QGEN) believes that the partnership will aid in improvising the automation of pre-analytic manual steps, leading to its QuantiFERON-TB Gold Plus test.